Novo Nordisk | NVO - Operating Profit


Novo Nordisk reported DKK5.18B in Operating Profit for its fiscal quarter ending in June of 2025.





Operating Profit Change Date
ANI Pharmaceuticals USD 22.83M 7.66M Sep/2025
Aurora Cannabis CAD -55.67M 35.45M Sep/2025
Bausch Health Companies USD 719M 2M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Canopy Growth CAD -14.3M 3.18M Sep/2025
Corcept Therapeutics USD 4.49M 5.73M Dec/2025
Drreddys Laboratories INR 14.33B 2.51B Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Merck USD 6.24B 318M Dec/2025
Nektar Therapeutics USD -34.34M 15.43M Sep/2024
Novartis USD 4.5B 363M Sep/2025
Novo Nordisk DKK 32.38B 1.7B Dec/2025
Novo Nordisk DKK 5.18B 33.61B Jun/2025
Pacira USD 13.15M 2.92M Sep/2025
Perrigo USD 93.4M 37.8M Sep/2025
Phibro Animal Health USD 25.53M 7.83M Dec/2024
Prestige Brands USD 82.49M 2.82M Dec/2025
Sanofi EUR 1.7B 2.17B Dec/2025
Supernus Pharmaceuticals USD 13.82M 74.01M Dec/2025
Zoetis USD 835M 101M Dec/2025